Valuation : Sernova

Market Cap 49.09M 35.64M 30.64M 28.83M 26.31M 3.38B 49.35M 342M 132M 1.73B 134M 131M 5.5B P/E 2026 *
-5.2x
P/E 2027 * -4.33x
Enterprise Value 49.09M 35.64M 30.64M 28.83M 26.31M 3.38B 49.35M 342M 132M 1.73B 134M 131M 5.5B EV / Sales 2026 *
-
EV / Sales 2027 * 19.6x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 week+18.18%
Current month+18.18%
1 month+13.04%
3 months-13.33%
6 months-18.75%
1 week 0.1
Extreme 0.1
0.15
1 month 0.1
Extreme 0.1
0.15
3 years 0.1
Extreme 0.1
0.83
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+18.18%0.00%-27.78%-84.88% 30.08M
-8.81%-12.91%-29.68%-4.53% 116B
-3.57%-4.11%-27.36%-3.84% 12.12B
+4.27%+4.72%+101.39%+148.78% 10.46B
+0.15%-0.79%-53.17%-69.72% 4.17B
+0.42%-1.06%-29.62%+38.48% 2.46B
-0.16%-4.20% - - 1.93B
-1.49%+1.01%-25.63%-72.33% 1.82B
+0.20%-2.09%-23.12%-26.58% 1.56B
Average -1.12%-2.36%-14.37%-9.33% 18.85B
Weighted average by Cap. -6.79%-10.38%-20.82%+4.10%

Financials

2026 *2027 *
Net sales - 2.5M 1.81M 1.56M 1.47M 1.34M 172M 2.51M 17.39M 6.73M 87.94M 6.81M 6.67M 280M
Net income -11.3M -8.2M -7.05M -6.64M -6.06M -778M -11.36M -78.62M -30.42M -397M -30.8M -30.13M -1.26B -13.9M -10.09M -8.68M -8.16M -7.45M -957M -13.97M -96.71M -37.41M -489M -37.89M -37.06M -1.56B
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
26-09-08 $0.1300 +18.18%
26-09-04 $0.1100 -4.35%
26-09-03 $0.1150 0.00%
26-09-02 $0.1150 +4.55%
26-09-01 $0.1100 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1300CAD
Average target price
1.000CAD
Spread / Average Target
+669.23%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!